Testimonial | Dr Emma Wood
Dr Emma Wood has been in the racing industry most of her life but was a late bloomer to the veterinary world. She has been an assistant trainer both…
Understanding Equine Arthritis: An Owners Guide to Treatment and Ethical Considerations
Navigating the Treatment Pyramid, Orthobiologics, and the Nutraceutical Conundrum Introduction Equine arthritis is a prevalent and concerning health issue that affects horses worldwide. It not only poses welfare challenges…
Arthramid Vet Expands its Presence in the Middle East
Dr Jason Lowe recently spent a few weeks in the Middle East, establishing relationships and sharing his knowledge with executives from some of the top Equine Care Centres and Veterinary…
New Joint Therapies in Animals
As veterinarians we understand the complexity of disease processes associated with joint pain remains a constant dilemma in clinical practice and as with any disease process, an accurate diagnosis is…
Product Testimonial – Consider Arthramid Vet as a better treatment option for older patients or those with underlying metabolic disease.
Non-Pharmacological treatment offers veterinarians a better option for older and metabolic patients suffering from osteoarthritis (OA). Arthramid Vet’s 2.5% iPAAG technology is injected directly into the joint space providing lubrication…
Arthramid Vet: The last chance treatment that pulled through
Archie, a 7-year-old warmblood gelding on the brink of retirement due to persistent joint pain and inflammation has been given a second chance thanks to the innovative technology of the…
Japan Racing Association confirm no ban on the use of 2.5% polyacrylamide (PAAG) product Arthramid® Vet in Japan
Japan Racing Association (JRA) Anti-Doping Statement Regarding 2.5% PAAG Arthramid® Vet. The Japan Central Racing Association Feed and Drug Inspection Supervisory Committee Secretariat Anti-Doping Division, Horse Affairs Department have…
New technologies to aid in treatment of osteoarthritis in dogs
Osteoarthritis (OA) is one of the most common chronic musculoskeletal diseases in dog populations, causing lameness and a loss of quality of life. It is estimated that 20-37% of dogs>…
Dr Florent David presentation on 2.5% PAAG Arthramid Vet
View On Demand. VetFest Marketplace – A dedicated Industry Week for the Veterinary Profession View this 40 minute video presentation as Dr Florent David (DVM, MS, Dipl. ACVS & ECVS,…
Cutting Edge Treatment Helps Champion Racehorse.
Sound is a 9 year-old TB stallion from Germany trained by Mike Moroney, who is based at Flemington, Australia. Given that Sound has won at Group 1 level and has…
Management of Joint Lameness in Competition and Sport Horses
Osteoarthritis (OA) is considered the most important musculoskeletal disorder in both humans and horses. From a clinical perspective it is associated with lameness and dysfunction of the affected joint, and…
Japan Racing Association (JRA)
Japan Racing Association (JRA) institute Laboratory for Racing Chemistry testing confirms Arthramid® Vet is free of Prohibited Substances in Japan Racing. To provide assurances to veterinarians in Japan, a representative…
